Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML

Limited treatment options are available for patients with relapsed/refractory acute myeloid leukemia (R/R AML). We recently reported results from the phase 3 IDHENTIFY trial (NCT02577406) showing improved response rates and event-free survival with enasidenib monotherapy compared with conventional c...

תיאור מלא

מידע ביבליוגרפי
Main Authors: Risueño, A, See, WL, Bluemmert, I, de Botton, S, DiNardo, CD, Fathi, AT, Schuh, AC, Montesinos, P, Vyas, P, Prebet, T, Gandhi, A, Hasan, M
פורמט: Journal article
שפה:English
יצא לאור: Elsevier 2024